

## **Product** Data Sheet

## P32/98 hemifumarate

Cat. No.: HY-129736 CAS No.: 251572-86-8

Molecular Formula:  $C_9H_{18}N_2OS_{.1}/_2C_4H_4O_4$ 

Molecular Weight: 260.36

Target: Dipeptidyl Peptidase

Pathway: Metabolic Enzyme/Protease

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

## **BIOLOGICAL ACTIVITY**

Description P32/98 hemifumarateis a potent inhibitor of dipeptidyl peptidase IV with a  $K_i$  value of 130 nM. P32/98 hemifumarate improves glucose tolerance, insulin sensitivity and β-cell responsiveness in fatty Zucker rat model<sup>[1][2][3]</sup>.

IC<sub>50</sub> & Target DPP-IV

130 nM (Ki)

In Vitro

GLP-1 acts function of stimulation of glucose dependent insulin secretion and induction of satiety feelings, and DPPIV is the major renal catabolic pathway for GLP-1 in vivo<sup>[2]</sup>.

P32/98 hemifumarate, together with 200 pM GLP-1, (10  $\mu$ M; 3 h) shows no significant inhibition of sodium re-absorption in porcine proximal tubular cells<sup>[2]</sup>.

P32/98 hemifumarate (10  $\mu$ M; 96 h) does not influence the mRNA expression of GLP-1R, DPPIV, Na<sup>+</sup>/H<sup>+</sup> exchanger isoform 3 (NHE3), sodium-dependent glucose transporter slc5a1, slc5a2 (SGLT1, 2)<sup>[2]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay<sup>[2]</sup>

Cell Line:	Porcine proximal tubular cells
Concentration:	10 μΜ
Incubation Time:	96 hours
Result:	Showed no toxic.

In Vivo

P32/98 hemifumarate (25 mg/kg; i.g.; once daily) long-time treatment significantly improves the glucose tolerance in Zucker diabetic fatty rats, a model of IGT (impaired glucose tolerance)<sup>[3]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Zucker diabetic fatty rat <sup>[3]</sup>
Dosage:	25 mg/kg
Administration:	Oral gavage; once daily

Result:	Significantly improved the glucose tolerance in Zucker diabetic fatty rats.

## **REFERENCES**

- [1]. Augstein P, et al. Efficacy of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide (P32/98) in fatty Zucker rats with incipient and manifest impaired glucose tolerance. Diabetes Obes Metab. 2008;10(10):850-861.
- [2]. Schlatter P, et al. Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells. Regul Pept. 2007 Jun 7;141(1-3):120-8.
- [3]. Wargent E, et al. Improvement of glucose tolerance in Zucker diabetic fatty rats by long-term treatment with the dipeptidyl peptidase inhibitor P32/98: comparison with and combination with rosiglitazone. Diabetes Obes Metab. 2005;7(2):170-181.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: } tech @ Med Chem Express.com$ 

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA